Sort
48,018 grants matching “immunotherapy”
Developing Novel Therapies for High Risk Pediatric Cancers
$922,580Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Systems genetics analysis of tumor evolution in the mouse
$922,470Allan Balmain · University Of California, San Francisco · R35 · FY2019 · CA
Immunoprevention and immunosurveillance of human non-viral cancers
$922,006Olivera J Finn · University Of Pittsburgh At Pittsburgh · R35 · FY2017 · CA
Regulatory T cells and the tumor microenvironment
$921,907Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · R35 · FY2025 · CA
Developmental Funds
$921,693Candace S Johnson · Roswell Park Cancer Institute Corp · P30 · FY2023 · CA
Targeting the DNA Damage Response sensor Replication Protein A for first inclass cancer therapy
$921,320Katherine Pawelczak · Nerx Biosciences, Inc. · R44 · FY2025 · CA
Broadly neutralizing SARS-CoV-2 peptidic knobs
$921,025Vaughn Vasil Smider · Applied Biomedical Science Institute · R01 · FY2025 · AI
Broadly neutralizing SARS-CoV-2 peptidic knobs
$921,025Vaughn Vasil Smider · Applied Biomedical Science Institute · R01 · FY2024 · AI
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability
$920,861Jana Portnow · Beckman Research Institute/City Of Hope · U19 · FY2022 · CA
Characterization Unit
$920,319David Liu · Dana-Farber Cancer Inst · U2C · FY2021 · CA
High Throughput & Quantitative Cell Purification for ImmunotherapyManufacture
$920,268Coleman Murray · Ferrologix, Inc. · R44 · FY2020 · CA
IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies
$920,225Nan Yang · General Nutraceutical Technology, Llc · R44 · FY2023 · AI
A single-cell device to capture and analyze rare T-cells from solid tumors.
$920,072Timothy S McConnell · Isoplexis, Inc. · R44 · FY2018 · CA
Using trained immunity-inhibiting nanobiologics to achieve tolerance of heart allografts in non-human primates
$919,879Joren C Madsen · Icahn School Of Medicine At Mount Sinai · P01 · FY2023 · AI
ApoVax104-HPV as a Novel Vaccine for Cervical Cancer
$919,441Kathryn J. Macleod · Apovax, Inc. · R44 · FY2008 · AI
Development of novel immunotherapy for influenza virus infection
$919,127Kazue Takahashi · Massachusetts General Hospital · U01 · FY2009 · AI
Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies
$918,854Samirkumar Patel · Moonlight Therapeutics, Inc. · R42 · FY2022 · AI
Defining the Importance of Immunity to NY-ESO-1 in Melanoma Therapy and Prognosis
$918,701Jedd D. Wolchok · Sloan-Kettering Inst Can Research · RC2 · FY2009 · CA
NextGen - CRI
$918,661Catherine Mary Bollard · Children'S Research Institute · OT2 · FY2024 · CA
Specialized Program Of Research Excellence (SPORE) in Leukemia.
$918,606Daniel C Link · Washington University · P50 · FY2023 · CA
Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control
$918,483M. Javad Aman · Abvacc, Inc. · R44 · FY2024 · AI
Identification of Lethal Melanomas at the Time of Diagnosis
$918,430Nancy E Thomas · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Monoclonal antibody-based intervention against SIV in nonhuman primates
$918,252Rosemarie Mason · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
CANCER AND LEUKEMIA GROUP B
$918,123Brigham And Women'S Hospital · U10 · FY2002 · CA
WASHINGTON D.C. CONSORTIUM PEDIATRIC AIDS CLINICAL TRIAL
$917,826Children'S National Medical Center · U01 · FY2001 · AI